Our website uses cookies to enable essential features and improve your browsing experience. Additionally, cookies enhance overall website functionality and user experience. By choosing I Accept, you agree to our use of non-essential cookies and other tracking technologies.

You have the ability to manage your settings or withdraw your consent at any time. We are committed to maintaining the privacy and security of your personal information. For detailed information on how we use cookies, including how to manage your privacy and preferences, please visit our cookie policy .
Developmentaid logo
Register
Print
Print
BioNTech SE

BioNTech SE

General
Jobs • 0
Shortlists/Awards • 11
Pricing strategy • 0
Partners/Competitors • 56
Tenders 2
Last update: May 27, 2026 Last update: May 27, 2026
General
Jobs
Shortlists/Awards
Pricing strategy
Partners/Competitors
Tenders

Details

Legal residence:Germany
Organization type:Other business entity
Funding agencies:EC, WB, Other, FP7, Horizon 2020, Gates Foundation ...
European Commission Directorate-General for International Partnerships (EuropeAid HQ), World Bank HQ, Other, The Seventh Framework Programme, Horizon 2020 (2014 - 2020), Gates Foundation, Horizon Europe (2021 - 2027)
Sectors:Health, Research & Innovation
 Health, Research & Innovation
Nr. of employees:1001-5000
Sanctions:
Status:
Active

Attachments • 0

About

Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases.

BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health of people worldwide. We believe that scientific rigor and passion are the driving forces that are essential for innovative progress.

BioNTech was founded in 2008 by scientists and physicians to translate science into survival by combining fundamental research and operational excellence. At BioNTech, we have been conducting fundamental research of mRNA technologies in the field of individualized cancer medicine for more than a decade. Some of our colleagues, including our co-founders, have been researching and developing mRNA-based vaccines for more than 25 years.

Awards

Top partners

Top competitors

Want to unlock full information?
Register with us or sign in to access the organization database.
Learn more about our membership benefits
Associated Experts
There are no experts associated to this organization.